Skin GLOW Stack
Comprehensive skin-and-recovery blend (GHK-Cu + TB-500 + BPC-157 + KPV) dosed daily for collagen, healing, and anti-inflammatory support. Based on the GLOW/Upgraded-Glow blend ratios.
Model levels over time
% of sampled peakModel details: GHK-Cu (Copper Peptide) · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Legacy 0.96 h is unverified for administered-human intact GHK-Cu. No quantitative timing is imported from free-GHK degradation.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 0.96 hours
- Absorption half-life assumed
- 0.24 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (0.24 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Free GHK, intact GHK-Cu, total copper and endogenous baseline GHK are different analytes.
- Topical cosmetic concentrations and assay calibration ranges are not plasma Cmax.
- In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds.
Legacy 0.96 h is unverified for administered-human intact GHK-Cu. No quantitative timing is imported from free-GHK degradation.
- 1997 original rat GHK/HK analytical PK paper
GHK acetate given IV to rats, rapidly degraded toHK; freeGHK is not intactGHK-Cu.
ghk-cu-relative-timing-2026-10 · version 1
Model details: BPC-157 · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Relative timing from animal research; a human blood profile is not established.
Timing assumptions and sources
Rat IM 100 microgram/kg saline BPC157: half-life 17.1 min, Tmax 3 min. The 2-person human IV pilot reports safety biomarkers, not peptide concentration calibration.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 0.285 hours
- Absorption half-life assumed
- 0.009976653 hours
- Reference amount for the relative scale
- 1 mg
- The faster rate is inferred to match the 0.05 h source-scoped peak time; absorption half-life 0.009976653025332967 h is a mathematical shape parameter, not separately measured.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Animal IM timing does not establish human SC absorption or elimination.
- Do not use total radiolabel half-life: the radiolabel includes metabolites and recycled amino acids.
- Rat/dog Cmax must not be scaled into a human blood estimate.
- Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.
Rat IM 100 microgram/kg saline BPC157: half-life 17.1 min, Tmax 3 min. The 2-person human IV pilot reports safety biomarkers, not peptide concentration calibration.
- He et al.2022, original BPC157 rat/dog PK
Rat IM100 microgram/kg:17.1 min half-life and 3 min Tmax. Human extrapolation deliberately limited to relative timing.
- Lee and Burgess2025, two-person human IV pilot
Safety bloodwork and vital signs; no reported BPC157 plasmaPK endpoints in the abstract.
bpc-157-relative-timing-2026-10 · version 1
Model details: TB-500 (Thymosin Beta-4) · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Ruff 2010:40 healthy volunteers, single 42–1260 mg IV then daily 14 days; dose-dependent half-life. The legacy 1.92 h is not a verified SC half-life.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 1.92 hours
- Absorption half-life assumed
- 0.48 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (0.48 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Product sequence and route are unresolved for a generic TB-500 entry.
- Do not transplant the full-length IV peak or half-life to the 7-residue fragment.
- A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers.
Ruff 2010:40 healthy volunteers, single 42–1260 mg IV then daily 14 days; dose-dependent half-life. The legacy 1.92 h is not a verified SC half-life.
tb-500-relative-timing-2026-10 · version 1
Model details: KPV · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Legacy 0.48 h is not established by the transporter or mouse efficacy study.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 0.48 hours
- Absorption half-life assumed
- 0.12 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (0.12 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Cell-culture nanomolar efficacy and PepT1 uptake kinetics are not plasma concentration-time parameters.
- Oral mouse exposure cannot establish human SC F.
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.
Legacy 0.48 h is not established by the transporter or mouse efficacy study.
kpv-relative-timing-2026-10 · version 1
Different scales · each curve is normalized to its own peak. Compare timing and shape, not concentration or potency.
| Date | GHK-Cu (Copper Peptide) · Relative timing (% of sampled peak) | TB-500 (Thymosin Beta-4) · Relative timing (% of sampled peak) | KPV · Relative timing (% of sampled peak) | BPC-157 · Relative timing (% of sampled peak) |
|---|---|---|---|---|
| W1 | 0 % of sampled peak | 0 % of sampled peak | 0 % of sampled peak | 0 % of sampled peak |
| W1 | 0.0035122 % of sampled peak | 0.862139 % of sampled peak | 5.82818e-8 % of sampled peak | 9.26999e-15 % of sampled peak |
| W2 | 2.49269 % of sampled peak | 22.9386 % of sampled peak | 0.0293572 % of sampled peak | 0.000037218 % of sampled peak |
| W3 | 0.00000630776 % of sampled peak | 0.0365364 % of sampled peak | 1.87986e-13 % of sampled peak | 5.22869e-24 % of sampled peak |
| W3 | 0.00421327 % of sampled peak | 0.944273 % of sampled peak | 8.38713e-8 % of sampled peak | 1.71128e-14 % of sampled peak |
| W4 | 2.99026 % of sampled peak | 25.1138 % of sampled peak | 0.0422469 % of sampled peak | 0.0000687058 % of sampled peak |
| W4 | 0.00000712146 % of sampled peak | 0.0388215 % of sampled peak | 2.39614e-13 % of sampled peak | 7.86841e-24 % of sampled peak |
| W5 | 0.00505428 % of sampled peak | 1.03423 % of sampled peak | 1.20696e-7 % of sampled peak | 3.15908e-14 % of sampled peak |
| W6 | 3.58714 % of sampled peak | 27.4918 % of sampled peak | 0.060796 % of sampled peak | 0.000126833 % of sampled peak |
| W6 | 0.00000854298 % of sampled peak | 0.0425199 % of sampled peak | 3.4482e-13 % of sampled peak | 1.45254e-23 % of sampled peak |
| W7 | 0.00606317 % of sampled peak | 1.13276 % of sampled peak | 1.7369e-7 % of sampled peak | 5.83178e-14 % of sampled peak |
| W8 | 4.30315 % of sampled peak | 30.09 % of sampled peak | 0.0874893 % of sampled peak | 0.000234139 % of sampled peak |
| W8 | 0.0000102482 % of sampled peak | 0.0465707 % of sampled peak | 4.96219e-13 % of sampled peak | 2.68144e-23 % of sampled peak |
The chart uses a bounded time grid. Long horizons can miss brief peaks between samples; shorten the horizon to inspect more detail. Chart peaks are sampled values.
Protocol summary
Skin GLOW Stack · 8 weeks starting Oct 15, 26
- GHK-Cu (Copper Peptide) — 1.25 mg Every day, weeks 0–8
- BPC-157 — 250 mcg Every day, weeks 0–8
- TB-500 (Thymosin Beta-4) — 500 mcg Every day, weeks 0–8
- KPV — 250 mcg Every day, weeks 0–8
Protocol overview
- Category
- peptide stack
- Duration
- 8 weeks
- Compounds
- 4
- Tags
- cosmetic, skin, glow, ghk-cu, bpc-157, tb-500, kpv, blend, peptide
Compounds in this protocol
How to read this protocol
The chart shows available model curves over the 8-week example. Rows whose model is unavailable are retained for context but produce no curve. Read each model’s details for what its line represents; a plotted level does not predict treatment effects or establish a suitable dose.
The peak/trough explorer examines one complete model interval. The single-dose decline explorer is a separate one-dose scenario; it does not calculate this protocol's washout or a safe treatment-change date. The compound comparison shows available model outputs, not equivalent clinical effects.
Educational only. Not medical advice. These examples do not predict individual blood levels.